$6.70+0.44 (+7.03%)
At close: Nov 18, 2026, 4:00 PM ET· Nasdaq · USD
ImmunityBio (IBRX) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
8 figures withheld by our checks. Each blank figure names its reason.
Business engineGrowing fast: revenue compounds ~231.9%/yr (FY21→FY25), net margin −310.2%. Worth your attention in FY25: Share count (+136.3%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲668.3%
113.3
FY21→FY25CAGR +231.9%/yr
Net income ($M)▲15.0%
−351.4
FY21→FY25CAGR —
Free cash flow ($M)▲22.3%
−309.2
FY21→FY25CAGR —
Diluted EPS▲38.7%
−0.38
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+136.3%
389.2mn → 919.9mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$4.3M
−38.3% YoY in FY25 · 3.8% of revenue.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($K)
-310¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 100.0% → 99.3%. Net margin -310.2% is below the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 182,572.0 | 113,288.0 | 14,745.0 | 622.0 | 240.0 | 934.0 | ▲668.3% | +231.9% |
Cost of revenue | 2,209.0 | 753.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | 180,363.0 | 112,535.0 | —A | —A | —A | 934.0 | — | — |
Research & development | 264,202.0 | 218,559.0 | 190,144.0 | 232,366.0 | 248,149.0 | 195,958.0 | ▲14.9% | +2.8% |
Selling, general & admin | 190,319.0 | 150,003.0 | 168,783.0 | 129,620.0 | 102,708.0 | 135,256.0 | ▼11.1% | +2.6% |
Total operating expenses | 454,521.0 | 368,562.0 | 358,927.0 | 362,872.0 | 351,538.0 | 331,214.0 | ▲2.7% | +2.7% |
Operating incomefeeds ROC rank | −274,158.0 | −256,027.0 | −344,182.0 | −362,250.0 | −351,298.0 | −330,280.0 | ▲25.6% | — |
Other income, net | −835,678.0 | −95,580.0 | −69,463.0 | −221,642.0 | −65,988.0 | −19,559.0 | — | — |
Pretax income | −1,109,836.0 | −351,607.0 | −413,645.0 | −583,892.0 | −417,286.0 | −349,839.0 | ▲15.0% | — |
Income tax | −170.0 | −135.0 | 0.0 | −40.0 | 34.0 | 9.0 | — | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −1,109,654.0 | −351,398.0 | −413,564.0 | −583,196.0 | −416,567.0 | −349,848.0 | ▲15.0% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −1.08 | −0.38 | −0.62 | −1.15 | −1.04 | −0.89 | ▲38.7% | — |
Diluted shares (bn) | 1.06 | 0.92 | 0.70 | 0.51 | 0.40 | 0.39 | ▲31.3% | +24.0% |
| Margins | ||||||||
Gross margin98th pct in Healthcare | 98.8% | 99.3% | —A | —A | —A | 100.0% | — | — |
Operating margin | −150.2% | −226.0% | −2334.2% | −58239.5% | −146374.2% | −35361.9% | ▲2108.2pp | +35135.9pp |
Net margin6th pct in Healthcare | −607.8% | −310.2% | −2804.8% | −93761.4% | −173569.6% | −37457.0% | ▲2494.6pp | +37146.8pp |
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
5 more years of statements and CSV export are on Premium, and 8 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-23 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was ImmunityBio's revenue last fiscal year?
ImmunityBio reported revenue of $113.3M in fiscal 2025, up 668.3% from fiscal 2024.
What was ImmunityBio's net income?
ImmunityBio reported net income of −$351.4M in fiscal 2025, a net margin of −310.2%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

